



DON'T MISS THE **CARDIOVASCULAR** EXPERT THEATER SESSIONS

Enjoy a complimentary lunch* while learning the latest advances in cardiovascular practices, services and technologies.

SATURDAY

BOOTH	SESSION START/END TIME	SUPPORTER	TITLE
250	Noon-12:45 p.m.	Janssen Biotech, Inc.	Clinical Information For Patients With Thrombotic Risk
	1:15-2 p.m.	Amgen, Inc.	Repatha® (evolocumab) Putting it Into Practice
	3:15-4 p.m.	Boehringer Ingelheim Corp.	Embolic Stroke of Undetermined Source
2002	Noon-12:45 p.m.	Sanofi Regeneron	PRALUENT (Alirocumab) Injection – The Time to Treat is Now
	1:15-2 p.m.	Novartis Pharmaceuticals Corp.	HFrEF AND SUDDEN CARDIAC DEATH: INSIGHTS FROM A LARGE HF OUTCOME STUDY
2038	Noon-12:45 p.m.	Amgen, Inc.	Understanding the Spectrum of LDL-C in CV Disease: A Focus on Low LDL-C
	1:15-2 p.m.	Boehringer Ingelheim Corp. Eli Lilly	Jardiance® (empagliflozin) tablets: Evolving Clinical Development

SUNDAY

BOOTH	SESSION START/END TIME	SUPPORTER	TITLE
250	10:15-11 a.m.	Amarin Corp.	Does VASCEPA® (icosapent ethyl) Prevent Cardiovascular Disease? New data from REDUCE-IT™
	Noon-12:45 p.m.	Amgen, Inc.	Who Are The Highest Risk CV Patients & How Do We Manage Them?
	1:15-2 p.m.	Novartis Pharmaceuticals Corp.	<i>To Be Announced</i>
	3:15-4 p.m.	Janssen Pharmaceuticals, Inc.	Long-Term Results of Treatment Across a Broad Range of Patients With Type 2 Diabetes
2002	Noon-12:45 p.m.	Novartis Pharmaceuticals Corp.	Expert Conversations in Heart Failure With Preserved Ejection Fraction
	1:15-2 p.m.	BMS Pfizer	Diagnosing Atrial Fibrillation: Current Challenges and the Future Connected World
2038	Noon-12:45 p.m.	Janssen Biotech, Inc.	Clinical Information For Patients With Thrombotic Risk
	1:15-2 p.m.	Amgen, Inc.	Repatha® (evolocumab) Putting it Into Practice

MONDAY

BOOTH	SESSION START/END TIME	SUPPORTER	TITLE
2002	Noon-12:45 p.m.	Amarin Corp.	Cardiovascular Risk Reduction with VASCEPA® (icosapent ethyl): Data from REDUCE-IT™

*Provided to attendees by the American Heart Association.
 This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.